Clinical Scorecard: Patient Profiles, Treatment Approaches, and Disease Burden in Alopecia Areata in Mexico

At a Glance

Key Highlights

• Patients with moderate to very severe AA had greater clinical involvement, including more extensive scalp and nonscalp hair loss, impaired quality of life, and higher anxiety and depression levels.
• Treatment across severity categories primarily comprised conventional therapies, especially corticosteroids.
• Advanced therapies were infrequently used, including among patients with severe/very severe AA.
• Patients with severe/very severe AA reported lower treatment satisfaction than those with mild or moderate disease.
• The authors identify substantial unmet treatment needs and suggest potential access and reimbursement barriers in Mexico.

Guideline-Based Recommendations

Diagnosis

Management

Monitoring & Follow-up

Risks

• The article states that conventional AA treatments generally have limited efficacy and are associated with adverse effects that restrict long-term use.
• The article reports limited access in Latin America, including Mexico, to JAK inhibitors and other advanced therapies, as well as certain conventional options such as systemic corticosteroids, because public healthcare systems do not routinely reimburse these treatments.

Patient & Prescribing Data

Adults aged 18 years or older with diagnosed AA in Mexico. The source excerpt does not provide enough information to verify the patient sampling sequence or severity quotas.

Clinical Best Practices

• The study reports that patients with moderate to very severe AA had greater clinical involvement, impaired quality of life, and higher anxiety and depression levels.
• The cited 2013 Mexican guidelines specify intralesional corticosteroids as first-line treatment and potent topical corticosteroids as an alternative.
• The cited guidelines list topical immunotherapy, minoxidil, phototherapy or photochemotherapy, and systemic therapies for refractory or more extensive disease.
• The article notes that conventional treatments may have limited efficacy and adverse effects that restrict long-term use.

Related Resources & Content

• Article: Patient Profiles, Treatment Approaches, and Disease Burden in Alopecia Areata in Mexico